TYH Capital
VC Fund
TYH Capital is a VC fund focused on Artificial Intelligence and SaaS. TYH Ventures enables entrepreneurs to turn their own ideas and visions into successful companies. It invests in its companies and gives its partners personal guidance from the very first stages and provided them with all the resources and expert advice they need to turn their visions into disruptive reality.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries TYH Capital invests in
Stages TYH Capital invests in
Countries TYH Capital invests in
Investment Focus
Industry
- Artificial Intelligence 3 (43%)
- SaaS 1 (14%)
- FinTech 1 (14%)
- Big Data 1 (14%)
- Analytics 1 (14%)
Stage
- Series A 2 (29%)
- Pre-Seed 1 (14%)
- Series B 1 (14%)
- Series C 1 (14%)
- Series D 1 (14%)
Country
- United States 4 (57%)
- Singapore 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M / Jul 17, 2024 | |
|
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M / Series D / Jul 17, 2024 | |
Platflow Health
|
Platflow Health is a gen AI-workflow platform that leverages real-time data, intelligent code identification, and compliant documentation pioneering a decentralized EMR to gain a strategic partner in increasing reimbursement, reducing compliance risks, streamlining operations, and elevating patient care. | $5M / Pre-Seed / Feb 11, 2024 | |
Terzo
|
Terzo Technologies is a cloud computing company that develops Vendor Relationship Management software. Terzo is the 1st SaaS platform that brings customers and vendors together to change the way organizations interact with their vendors.Terzo VRM is designed to improve collaboration, manage IT assets and take control of contracts & spend. | $12M / Series A / Nov 16, 2022 | |
Silent Eight
|
Silent Eight is a technology company leveraging AI to create custom compliance models for the world's leading financial institutions. Our mission is to empower our clients in their fight to eliminate financial crime. Founded in Singapore and with global hubs in New York, London, and Warsaw, we are deployed in over 150 markets. For moreinformation, visit: www.silenteight.com | $40M / Series B / Feb 18, 2022 | |
Hayden AI
|
Hayden AI’s mission is to develop cutting-edge artificial intelligence and machine learning technologies that enable the automated enforcement of bus lanes and stops—accelerating public transit, improving street safety, and advancing a more sustainable urban future. | $20M / Series A / Aug 19, 2021 | |
|
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $105M / Series C / Feb 24, 2021 |
Co-Investors
7wire Ventures
3 deals together
DNS Capital
3 deals together
GreatPoint Ventures
3 deals together
Wittington Ventures
3 deals together
Medical Excellence Capital
2 deals together
Tao Capital Partners
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does TYH Capital invest in?
TYH Capital invests primarily in Artificial Intelligence, SaaS and FinTech startups, most often at Series A and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did TYH Capital last invest?
The most recent investment recorded for TYH Capital closed in Jul 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
